AM-4030
| AM-4030 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
AM-4030 is a synthetic cannabinoid that was developed for research purposes. It is structurally related to other cannabinoids and has been studied for its potential effects on the endocannabinoid system.
Chemical Structure[edit]
AM-4030 belongs to a class of compounds known as cannabinoids, which interact with the cannabinoid receptors in the brain and body. The chemical structure of AM-4030 includes a dibenzo[b,d]pyran ring system, which is a common feature in many synthetic cannabinoids.
Pharmacology[edit]
AM-4030 acts as an agonist at the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain, mood, and appetite.
Research and Applications[edit]
Research on AM-4030 has primarily focused on its interaction with the endocannabinoid system and its potential therapeutic applications. Studies have investigated its effects on pain management, neuroprotection, and anti-inflammatory properties.
Legal Status[edit]
The legal status of AM-4030 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its potential for abuse and psychoactive effects.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
